Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million on August 31, 2023. Transaction is subject to Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and Morris, Nichols, Arsht & Tunnell LLP served as legal advisors to EPI Health, LLC and K&L Gates LLP served as legal advisor to Mayne Pharma Group Limited (ASX:MYX).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.665 AUD | -1.17% | -4.80% | -24.15% |
Jun. 03 | Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland | MT |
May. 24 | Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.15% | 253M | |
+20.30% | 43.46B | |
+25.60% | 22.61B | |
+16.89% | 15.15B | |
+23.35% | 14.83B | |
+57.78% | 13.08B | |
-0.05% | 6.79B | |
-12.36% | 6.72B | |
-8.87% | 5.73B | |
+12.71% | 5.45B |
- Stock Market
- Equities
- MYX Stock
- News Mayne Pharma Group Limited
- Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.